Glaxo ready for fresh court battle
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GLAXO yesterday limbered up for another battle to protect its rights to Zantac, its best-selling ulcer drug, when it started patent infringement proceedings against Novopharm, the generic manufacturer, in the US, writes Heather Connon.
Glaxo had been expecting attacks on its Form 1 patent for Zantac, which expires in the US in December 1995. It has always said that it is impossible to make Form 1 without also making Form 2, which is the basis used for the drug. The Form 2 patent does not expire until 2002.
Because rival manufacturers would not have to recoup the research costs of developing the drug, they would be able to undercut the price charged by Glaxo substantially.
Yesterday afternoon Novopharm hit back, calling Glaxo's legal action frivolous, and announcing that it intends to file a countersuit. 'Glaxo are really groping around with this lawsuit,' Leslie Dan, Novopharm chairman said. 'We are very optimistic that we shall prevail.' Mr Dan added that if court proceedings delay Novopharm's introduction of its rival to Zantac when Form 1 comes off patent at the end of 1995, Novopharm will sue Glaxo for delayed sales and seek punitive damages.
Novopharm is also challenging Glaxo's patent on Form 2 and is appealing against a court judgment last September upholding the patent. Glaxo also faces a challenge from Genpharm, another manufacturer of generic drugs.
Glaxo's shares fell 14p to 574p.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments